Navigation Links
UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis
Date:10/17/2009

or equal to 0.001).

(+) Post hoc analysis of RAPID 1

The post hoc analysis of the RAPID 1 study aimed to determine if a more rapid response to certolizumab pegol, together with MTX, was associated with better long-term improvements in physical function, and relief of pain and fatigue, in the treatment of active RA in patients who did not respond to conventional treatment. Patients who responded to treatment with certolizumab pegol 200 mg every two weeks by Week 12 were divided into two subgroups: The earlier Week 6 responders and later Week 12 responders based on responder definitions: ACR20 response or DAS28 change of greater than or equal to 1.2 from baseline. The early Week 6 DAS and ACR20 responders had a higher probability of achieving ACR20/50/70 scores at Week 52 (p < 0.001). By ACR20 definition, 83.1% of the early Week 6 responders maintained an ACR20 response at Week 52 compared to 66.7% of the later Week 12 responders (p < 0.001).

(++) Open label extension study to RAPID 1(028)

The Phase III, open-label extension (OLE) study to RAPID 1 is investigating the long-term efficacy and safety of subcutaneous certolizumab pegol (400 mg every 2 weeks) together with methotrexate in the treatment of signs and symptoms and in the prevention of joint damage in patients with active RA. Patients completing RAPID 1 through 52 weeks (completers), or who were ACR20 nonresponders at Week 12 (confirmed at Week 14) and were to be withdrawn from the study at Week 16 (withdrawers), could continue in the 028 study. The open-label extension study continued to evaluate the effects of certolizumab pegol( )over two years. This analysis was performed in completers (n= 508) with 100 weeks of exposure from RAPID 1 baseline. 95.8% of completers entered open-label treatment, and of these, 91.1% continued in the study after 100 Weeks. ACR response rates in these patients
'/>"/>

SOURCE UCB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohns Patients
2. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
3. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
4. Tiny test tube experiment shows reaction of melting materials at the nano scale
5. New Survey Shows Devastating Impact of Rheumatoid Arthritis Pain on Intimate Relations
6. Topical erectile dysfunction therapy shows promise
7. Study on keeping nuclear bombs from US ports shows misplaced fear over cargo scanning cost
8. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
9. Video shows nanotube spins as it grows
10. MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
11. Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
(Date:9/22/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property development ... today announced that the United States Patent & Trademark Office ... month of September that is part of a standard essential ... USRE45,121 , Application number: US 13/728,867 , ... 27, 2012 The listed inventors of the ...
(Date:9/21/2014)... Chemical Sciences play a significant role in meeting ... safe water, healthy food, and dependable medicine from ... educators, and scientists have a great role in ... for the national development, and to foster research ... emerging Sciences, accelerating with a tremendous speed to ...
(Date:9/20/2014)... 20, 2014 MediVet America ... a groundbreaking surgery at the specialized Wolvega Horse Clinic. ... digital flexor tendon was ruptured 90% and her deep ... is a death sentence for a horse. , The ... cell treatments . This revolutionary regenerative option for ...
Breaking Biology Technology:Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 2World’s first tendon replacement using Nanofiber and activated MediVet Stem Cell Fraction 3
... 24 Huntsman Advanced Materials, a division ... announced it was awarded the JEC Award for innovative ... Huntsman received the award for the innovative use of ... with its US-based customer GrafTech International.Andre Genton, President of ...
... S.A. and,Solvay Pharmaceuticals Marketing and Licensing AG (subsidiary ... partnership agreement for the,promotion and distribution of Stallergenes ... of Independent States (CIS). , ... and a strong demand on the,part of the ...
... than 80% of Nearly 4,000 Participants Attend InformexUSA ... Chemical IndustryPRINCETON, N.J., March 24 In a ... the United States -- InformexUSA -- visitors affiliated ... said they remain on the look-out for new ...
Cached Biology Technology:Huntsman Innovation Wins Top Award at Paris JEC Show 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 2Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS* 3Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond 2Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond 3
(Date:9/21/2014)... newborn immune T cells may have the ability to ... new study led by King,s College London. Although their ... babies may still be able to mount a strong ... Nature Medicine . , Our immune system is ... including neutrophils which play an important role in the ...
(Date:9/19/2014)... unveiled today by researchers from several Harvard University ... both experienced and aspiring researchers with the intellectual ... robots made from soft, flexible materials. , With ... and other advances in manufacturing technology, soft robotics ... principles drawn from conventional rigid robot design, but ...
(Date:9/19/2014)... species which over thousands of years has adapted to the ... that makes the cold dangerous for you. , This is ... and the cold provoking substance, called nonylphenol, comes from the ... suspected of being a endocrine disruptor, but when entering the ... ability to protect the cells in its body from cold ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... to act cancerous, surviving, growing and reproducing out of ... characteristics to stop growing or to die. In breast ... sometimes promoting tumors and sometimes suppressing them. A ... the journal Oncogene details how tumors may ...
... of Texas at Austin researchers have demonstrated a new ... the heart and limbs a research advancement that ... disease, the leading cause of death in the Western ... of Engineering Assistant Professor Aaron Baker could allow doctors ...
... available in German . The Deutsche ... four new Research Units. This decision was taken by the ... of the research consortia is to offer researchers the opportunity ... and to establish innovative research directions. As with ...
Cached Biology News:Study details on-off switch that promotes or suppresses breast cancer 2New ability to regrow blood vessels holds promise for treatment of heart disease 2New ability to regrow blood vessels holds promise for treatment of heart disease 3DFG to establish 4 new research units 2DFG to establish 4 new research units 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: